Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application

This series of live workshops will cover the importance of LAG-3 as a new immunotherapy target and the emerging data on the mechanism of action use and safety of anti&ndash LAG-3 immunotherapies across a range of malignancies. Accompanying these workshops will be a downloadable slideset simulcasts an expert commentary a PDF practice resource and an on-demand webcast.

Live webinars!

Webinar 1 - June 28 2022

Webinar 2 - July 6 2022

Webinar 3 - July 19 2022

 

Share

Program Content

No activities added yet

Activities

Rela/Nivo 1L Melanoma
What to Know About the Novel Anti–LAG-3 Checkpoint Inhibitor Relatlimab in Melanoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 21, 2022

Expires: March 20, 2023

Activities

<i>ExpressPoints</i>: LAG-3 Mechanism of Action
ExpressPoints
LAG-3 Mechanism of Action
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

Targeting LAG-3 in Cancer
Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2022

Expires: March 22, 2023

Activities

LAG-3 Summary Resource
Understanding the Role of LAG-3 in Malignancies: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2022

Expires: March 22, 2023

Faculty

cover img faculity

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

cover img faculity

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb